PMC6237918_01
Skin lesions before rituximab treatment.
fmed-05-00315-g0001.jpg
PMC6237918_01_fmed-05-00315-g0001.jpg
F1
The clinical examination revealed multiple erythematous papules and plaques with crusts on his back, chest, face, and scalp (about 40% of body surface area was involved) with no mucosal involvement (Figure 1).
Clinical picture eight months after initial rituximab treatment.
fmed-05-00315-g0002.jpg
PMC6237918_01_fmed-05-00315-g0002.jpg
F2
Therefore, two rituximab infusions (1 g each) were administered 2 weeks apart leading to a near-complete b-cell depletion in peripheral blood, a decrease in Dsg1 antibody levels (below the detection range), and an almost complete remission of the skin lesions within the next year (Figure 2).